Sean H Lim|Peter W M Johnson - JoVE Visualize

Showing results (61-70 of 103) with videos related to

Pageof 11

Sort By:

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005

Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519)Peter W M Johnson, John A Radford, Michael H Cullen, et al.

Scientific Reports|May 24, 2022

Prognostic significance of crown-like structures to trastuzumab response in patients with primary invasive HER2 + breast carcinomaCharles N Birts, Constantinos Savva, Stéphanie A Laversin, et al.

The Lancet. Oncology|September 18, 2018

Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trialRichard A Anderson, Rachel Remedios, Amy A Kirkwood, et al.

The Lancet. Rheumatology|January 22, 2024

Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODYFiona A Pearce, Sean H Lim, Mary Bythell, et al.

Journal of Immunology (Baltimore, Md. : 1950)|June 29, 2022

KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer ActivityMatthew D Blunt, Andres Vallejo Pulido, Jack G Fisher, et al.

Nature Communications|December 20, 2025

Harnessing multivalency and FcγRIIB engagement to augment anti-CD27 immunotherapyMarcus A Widdess, Anastasia Pakidi, Hannah J Metcalfe, et al.

Blood Advances|July 28, 2020

BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expressionThomas E C Cummin, Kerry L Cox, Tom D Murray, et al.

Haematologica|November 28, 2015

The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trialSimon Rule, Paul Smith, Peter W M Johnson, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2009

Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244Peter J Hoskin, Lisa Lowry, Alan Horwich, et al.

Cancer Immunology Research|August 28, 2019

Cyclophosphamide Enhances Cancer Antibody Immunotherapy in the Resistant Bone Marrow Niche by Modulating Macrophage FcγR ExpressionAli Roghanian, Guangan Hu, Christopher Fraser, et al.

Pageof 11

Showing results (61-70 of 103) with videos related to

Sort By:

Pageof 11

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005

Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519)Peter W M Johnson, John A Radford, Michael H Cullen, et al.

Scientific Reports|May 24, 2022

Prognostic significance of crown-like structures to trastuzumab response in patients with primary invasive HER2 + breast carcinomaCharles N Birts, Constantinos Savva, Stéphanie A Laversin, et al.

The Lancet. Oncology|September 18, 2018

Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trialRichard A Anderson, Rachel Remedios, Amy A Kirkwood, et al.

The Lancet. Rheumatology|January 22, 2024

Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODYFiona A Pearce, Sean H Lim, Mary Bythell, et al.

Journal of Immunology (Baltimore, Md. : 1950)|June 29, 2022

KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer ActivityMatthew D Blunt, Andres Vallejo Pulido, Jack G Fisher, et al.

Nature Communications|December 20, 2025

Harnessing multivalency and FcγRIIB engagement to augment anti-CD27 immunotherapyMarcus A Widdess, Anastasia Pakidi, Hannah J Metcalfe, et al.

Blood Advances|July 28, 2020

BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expressionThomas E C Cummin, Kerry L Cox, Tom D Murray, et al.

Haematologica|November 28, 2015

The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trialSimon Rule, Paul Smith, Peter W M Johnson, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2009

Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244Peter J Hoskin, Lisa Lowry, Alan Horwich, et al.

Cancer Immunology Research|August 28, 2019

Cyclophosphamide Enhances Cancer Antibody Immunotherapy in the Resistant Bone Marrow Niche by Modulating Macrophage FcγR ExpressionAli Roghanian, Guangan Hu, Christopher Fraser, et al.

Pageof 11